Compare Church & Dwight Co., Inc. (CHD) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Church & Dwight Co., Inc. vs Recursion Pharmaceuticals Inc — how do they compare? Church & Dwight Co., Inc. trades at $97.03 (market cap $23.02B), while Recursion Pharmaceuticals Inc trades at $3.35 (market cap $1.75B). The key difference: Church & Dwight Co., Inc. is far larger — about 13.2× Recursion Pharmaceuticals Inc's market cap, and Church & Dwight Co., Inc. pays a 1.27% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| CHD | RXRX | |
|---|---|---|
Market Cap | $23.02B | $1.75B |
Sector | Consumer Staples | Health |
52-Week High | $105.26 | $6.79 |
52-Week Low | $81.60 | $2.84 |
Enterprise Value | $24.72B | $1.17B |
Dividend Yield | 1.27% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Church & Dwight Co., Inc.
Church & Dwight is the leading producer of baking soda in the world. Beyond baking soda, the products in its portfolio have vast category reach, including laundry products, cat litter, oral care, deodorant, and nasal care, all sold under the Arm & Hammer brand. Its mix also includes Xtra, Trojan, OxiClean, First Response, Nair, L'il Critters/Vitafusion, Orajel, and WaterPik, which together with Arm & Hammer constitute more than 80% of its annual sales and profits. In early 2019, the firm announced the addition of Flawless, which manufactures electric shaving products for women. At the end of 2020, the firm acquired Zicam, a leading brand in the cough/cold-shortening category. Church & Dwight derives more than 80% of its sales from its home market in the U.S.
Read more on CHD →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
